Top Banner
© 2012 Winston & Strawn LLP
49

© 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

Aug 06, 2020

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP

Page 2: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP

Securities Litigation in 2012 and Beyond: New Targets, New Solutions

Brought to you by Winston & Strawn’s Securities Litigation Practice Group

Page 3: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 3

Today’s eLunch Presenters: Topic 1

Casey Berger

LitigationHouston

[email protected]

John Roesser

LitigationNew York

[email protected]

Getting Out in Front of Shareholder Challenges to Mergers & Acquisitions

Page 4: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 4

Focus Has Shifted

Private Securities Litigation Reform Act of 1995 & recent Supreme Court decisions have made traditional stock drop cases much more difficult to allege

• Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation

• Tellabs 2007: inference of “scienter” (intent) must be more than merely “reasonable” or “permissible,” must be cogent & compelling

• Morrison 2010: limited extraterritorial application of securities laws

• Merck 2010: SOL begins running when plaintiffs actually or reasonably should have discovered facts forming claim

Financial Crisis Cases are on the decline

As a result, M&A cases are dramatically on the rise

Page 5: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 5

The Anatomy of a Typical Shareholder Challenge to a Merger or Acquisition

Transaction is announced

Multiple complaints filed soon thereafter (< 2 weeks)

Plaintiffs assert claims for breach of fiduciary duty against the board of directors, often alleging, initially, that the offer significantly undervalues company

Company has incentive to close transaction and thus seeks to quickly dispense with lawsuits

Page 6: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 6

The Overwhelming Majority of Deals Will Be Challenged

Chart taken from Cornerstone Research’s

“Recent Developments in Shareholder Litigation Involving Mergers and Acquisitions”

Page 7: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 7

M&A Cases Are No New Phenomenon

Chart taken from Cornerstone Research’s

"Recent Developments in Shareholder Litigation Involving Mergers and Acquisitions"

Page 8: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 8

M&A Deals Are Often the Subject of Multiple Lawsuits

Chart taken from Cornerstone Research’s

"Recent Developments in Shareholder Litigation Involving Mergers and Acquisitions"

Page 9: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 9

Shareholders Act Quickly . . .

Chart taken from Cornerstone Research’s

"Recent Developments in Shareholder Litigation Involving Mergers and Acquisitions"

Page 10: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 10

. . . And Their Lawyers Get Paid . . .

Chart taken from Cornerstone Research’s

"Recent Developments in Shareholder Litigation Involving Mergers and Acquisitions"

Page 11: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 11

. . . Even When the Shareholders Don’t

57 investor class actions settled or otherwise concluded in Delaware in 2010 and 2011

40—or 70 percent—made money for plaintiffs’ lawyers but not shareholders (disclosures only)

Judges are growing critical of disclosure – only settlements

Page 12: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 12

The Other 30%

Chart taken from Cornerstone Research’s

"Recent Developments in Shareholder Litigation Involving Mergers and Acquisitions"

Page 13: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 13

Plaintiffs Are Avoiding Federal Courts . . .

Chart taken from Cornerstone Research’s

"Recent Developments in Shareholder Litigation Involving Mergers and Acquisitions"

Page 14: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 14

While Delaware Is The Most Prominent Non-Federal Venue . . .

Chart taken from Cornerstone Research’s

"Recent Developments in Shareholder Litigation Involving Mergers and Acquisitions"

Page 15: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 15

Delaware Is No Walk in the Park

Complex law applied

Sophisticated, diligent, and thorough judges

Unwilling to sign off on standard & unearned fees

Little patience for meritless cases

• “I don’t think for a moment that 90 percent—or based on recent numbers, 95 percent of deals are the result of a breach of fiduciary duty. I think that there are market imbalances here and externalities that are being exploited. What this means is that this Court needs to think carefully about balancing.”

o Vice Chancellor, J. Travis Laster, Stourbridge Investments, LLC v. Bersoff, C.A. No. 7300-VCL (Del. Ch. Mar. 13, 2012) (emphasis added)

Page 16: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 16

. . . Plaintiffs Are Forum Shopping to Avoid It

Chart taken from Cornerstone Research’s

"Recent Developments in Shareholder Litigation Involving Mergers and Acquisitions"

Page 17: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 17

Post-Closing Litigation

Post-Closing litigation historically uncommon

Business Judgment Rule

Exculpation Provisions

Incentive for companies to settle prior to closing of transaction, particularly where plaintiffs seek to restrain closing

Plaintiffs instead pursue pre-closing settlements & disclosures

Judges are, however, growing increasingly critical of such cases and fear that they primarily result in attorneys’ fees

• 40 cases $32.4 million for lawyers & $0 for shareholders

• 17 M&A lawsuits only led to $350 million total for the shareholders

• Del Monte settled for $89.4 million $22.3 million in attorneys’ fees

Plaintiffs now willing to litigate given potential damages awards, especially if not in federal court or Delaware state courts

Page 18: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 18

M&A Litigation: Recent Example

In re El Paso Corporation Shareholder Litigation, C.A. No. 6949-CS (Del. Ch. Feb. 29, 2012)

Page 19: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 19

The Deal

El Paso Corporation (two main business lines: Pipeline and E&P) publically announced plan to spin-off the E&P business

Kinder Morgan submitted an offer to buy the entire company, but intended to spin-off E&P business to finance the deal

Merger talks begin August/September 2011 between El Paso & Kinder Morgan

El Paso’s longtime advisor Goldman Sachs was initially advising on E&P spin-off; due to potential conflicts, Morgan Stanley also brought in to advise on the Kinder Morgan Merger

El Paso CEO “undertook sole responsibility for negotiating the sale” to Kinder Morgan

Merger Agreement signed – October 16, 2011

Page 20: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 20

The Fallout

Multiple El Paso stockholders file class action suits challenging the Merger

22 putative class action lawsuits filed overall: 6 (DE) / 5 (TX) within 1 week

5 (DE) / 3 (TX) within 2 weeks

2 (DE) within 3 – 4 weeks

Cases consolidated in Delaware and lead counsel chosen

Page 21: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 21

Shareholders Take Issue

Shareholders file breach of fiduciary duty claims against Board and seek to enjoin the Merger. Key allegations: El Paso accepted a lower final bid ($25.91/share) than what was

previously offered ($27.55/share) $534M shortfall

Deal protection provisions

“No-shop” provision

$650 million termination fee and matching rights in event of Superior Proposal

Conflicts of interest with financial advisors and management

Page 22: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 22

The Conflicts

Conflicting motives of El Paso CEO: approached Kinder Morgan with proposal for management buy-out of E&Pbusiness late in process, which was not disclosed to Board

Goldman owned 19% of Kinder Morgan ($4 Billion)

Goldman controlled two Kinder Morgan Board seats

Goldman’s lead banker for El Paso had an undisclosed personal financial interest in Kinder Morgan worth $340,000

Morgan Stanley brought into immunize Goldman conflict; however, Morgan Stanley would only get paid if El Paso sold to Kinder Morgan (which would benefit original advisor Goldman)

Page 23: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 23

Unhappy Judge

Judge highly critical of players and process: Extremely “disturbing behavior” Board acted “weakly” during negotiations Revised lower bid that was ultimately accepted:

“Instead of telling Kinder [Morgan] where to put its drilling equipment, [the CEO] backed down.”

“Goldman’s friends in El Paso management—and this is what they seem to have been—easily gave in to Goldman”

Board and CEO “can be seen by a rational mind as oddly timid” “Some backbone might well have resulted in a better result” CEO’s “velvet glove negotiating strategy” viewed as having been

influenced by improper motive

Page 24: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 24

Business Judgment Protection May Be Compromised By Conflicts

Court reaffirms general Delaware notions that, under Revlon, so long as directors made reasonable decisions for a proper purpose, they met their duties and courts will not second-guess the board “Although a reasonable mind might debate the tactical choices

made by the El Paso Board, these choices would have little basis for enjoining a third-party merger approved by a board overwhelmingly comprised of independent directors”

Even so, the Court suggested that the customary deference to the Board in exercising its business judgment was undermined by the conflicts of the CEO and financial advisors upon which it relied

Page 25: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 25

No Injunction

Court determined that the shareholders had a reasonable probability of success on a claim that the Merger was tainted by breaches of fiduciary duty, however…

Injunction still denied – El Paso stockholders were sufficiently prepared to vote on the Merger and “decide for themselves”

Reasoning: injunction would cause more harm than good No rival bids existed

Roughly 35-45% premium over pre-announcement share price

Injunction would likely last beyond June 30, 2012, which is the drop-dead date in the Merger Agreement

Kinder Morgan would be allowed to walk away on that date

Page 26: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 26

Where Does the Deal Stand?

WSJ (Mar. 9, 2012): El Paso shareholders voted overwhelmingly to approve the sale to

Kinder Morgan (95% of the shares voted endorsed the deal; shareholders holding about 79% of outstanding shares voted)

Kinder Morgan has agreed to sell the E&P business to private-equity firm Apollo Global Management

Court mentions the likely prospect of a damages trial against the El Paso CEO, other El Paso managers who might be added as defendants, and financial advisors NYTimes (Mar. 7, 2012): California State Teachers’ Retirement

System said it would vote to block Kinder Morgan’s $21 billion takeover of El Paso, citing a lack of transparency and conflicts of interest related to the deal

Page 27: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 27

Considerations after El Paso

Consider appointing a special committee of independent and disinterested directors; Board should be actively involved in the process

Legal team should include/consider litigation perspective

Vet financial advisors and assess the impact of their potential conflicts before and throughout retention; Board should be prepared to explain financial advisors’ capabilities and why they were retained

Clearly define the financial advisor’s role and actively police

Carefully consider the incentives created by fee arrangements with financial advisors

Be prepared to defend the process and demonstrate that it was not compromised by conflicts

Page 28: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 28

Today’s eLunch Presenters: Topic 2

Robb Adkins

LitigationSan Francisco

[email protected]

Jack Knight

LitigationCharlotte

[email protected]

Dodd-Frank, Whistleblower Rules, FCPA, and What To Do When the Feds Come Knocking

Page 29: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 29

Dodd-Frank (2010)

Comprehensive financial regulation and restructuring

CFTC and SEC have rule-making authority and power to regulate derivatives

Tightened regulation of credit-rating agencies – SEC Office of Credit Ratings

New whistleblower rules from SEC and CFTC – SEC Office of the Whistleblower

SEC Office of Market Intelligence

Page 30: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 30

Overlapping Regulation Today

Example: Whistleblowers

SOX – strict compliance with procedures for receiving and investigating allegations

Dodd-Frank – bounties for whistleblowers Any action, any agency, not confined to shareholder

protection

Need not report internally first to receive monetary award

Compliance personnel eligible in certain circumstances

Good corporate citizens: What is a public company to do?

Page 31: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 31

What is on the Horizon in Federal Regulation and Enforcement?

Greater parallel enforcement

Increased focus on predictive modeling and triage –impact of Dodd-Frank whistleblower rules

Greater emphasis on matters with potentially large monetary penalties or recoveries

Page 32: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 32

How the SEC and DOJ Come Knocking

A “visit” or request for interview by Special Agents or investigators

Written Notice of Investigation

Target Letter (DOJ)

Notice of informal investigation (SEC)

Notice of formal investigation (SEC)

Wells Notice (SEC)

Grand Jury Subpoena (DOJ)

Subpoena Duces Tecum

Testimony

Search Warrant (DOJ)

Page 33: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 33

The Parallel Players

Department of Justice (DOJ)

Antitrust (ATR), Civil (CIV), Civil Rights (CRT), Criminal (CRM), U.S. Attorney’s Office (USAO), FBI, Bureau of Alcohol Tobacco & Firearms (BATF), Drug Enforcement Administration (DEA), Bankruptcy Trustees

Securities and Exchange Commission (SEC) – Enforcement Division

Other federal investigators/regulators

CFTC, FTC, IRS-CI, USSS, USPIS, ICE, DOL, FDA, OCC, FDIC, FRB, NCUA, SIGTARP, FinCEN

Offices of the Inspector General

State Attorneys General/local District Attorneys

State Regulators

Page 34: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 34

Financial Fraud Enforcement Task Force

Executive Order signed by President Obama establishing the FFETF on 11/17/2009

More than 25 Federal Agencies

Local and State Partners

Criminal, Civil, and Administrative Remedies

Broad scope of FFETF

Equally broad mandate

Page 35: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 35

ENFORCEMENT COMMITTEE

FINANCIAL FRAUD ENFORCEMENT TASK FORCE

TRAINING AND

INFORMATION

SHARING

COMMITTEE

STEERING COMMITTEE

VICTIMS’ RIGHTS

COMMITTEE

MORTGAGE

FRAUD

SECURITIES

AND

COMMODITIES

FRAUD

RECOVERY

ACT

FRAUD

TARP

FRAUDDISCRIM.RMBS

“Financial

Crisis”

Page 36: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 36

DOJ Criminal Division

Eric Holder,AG

U.S. Attorney’s Offices

(94 districts)

Lanny Breuer,AAG, Criminal

Division

Greg Andres,DAAG, Criminal

Division

Denis McInerney,Chief, Fraud

Section

Page 37: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 37

SEC Division of Enforcement

Robert Khuzami,Director

Lorin Reisner,Deputy Director

Asset Management Unit

Foreign Corrupt Practices Unit

Market Abuse Unit

Municipal Securities and Public Pensions Unit

Structured and New Products Unit

Office of Market Intelligence

Office of the Whistleblower

Regional Offices

Page 38: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 38

New SEC Formal Investigations Fiscal Years 1997 – 2011

Source: SEC

265 275 282

345324

300

254 261 272255

229 233

496

531

0

100

200

300

400

500

600

1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

578

2011

Page 39: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 39

SEC Enforcement Actions Filed Fiscal Years 2005 – 2011

Source: SEC

630

574

656

671664

681

520

540

560

580

600

620

640

660

680

700

2005 2006 2007 2008 2009 2010

735

2011

Page 40: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 40

The SEC Reorganization

Specialized Units:

Asset Management (investment advisers and hedge funds)

Market Abuse (insider trading and market manipulation)

Structured and New Products (derivative products)

Foreign Corrupt Practices Violations*

Municipal Securities and Public Pensions

New offices with focus on predictive modeling:

Office of Market Intelligence

Office of the Whistleblower

*New, unique SEC unit in San Francisco focused on FCPA.

Page 41: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 41

Tactical Considerations in Defending Parallel

Proceedings

Questions to Consider Cooperate and assist or prepare to defend?

If you cooperate, are you creating a roadmap for plaintiffs?

If you do not cooperate and assist, do you risk charges of obstruction?

By cooperating, do you risk waiving the attorney-client privilege?

Document Production

Witness Summaries

Written Report

Page 42: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 42

FCPA Trend No. 1: More and More FCPA

Dramatic increase in FCPA enforcement, with large surge in the past five years

Reportedly there are approximately 150 ongoing FCPA investigations by DOJ alone

Page 43: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 43

FCPA Trend No. 2: Continued Large Monetary Resolutions – Why?

A few examples of FCPA fines and disgorgement:

BAE Systems plc: $400 million criminal fine

Snamprogetti Netherlands B.V./ENI S.p.A.: $365 million ($240 million criminal penalty and, with former parent ENI, $125 million in disgorgement)

Technip S.A.: $338 million ($240 million criminal penalty and $98 million in disgorgement)

Daimler AG (along with two subsidiaries): $185 million ($93.6 million criminal penalty and $91.4 million in disgorgement)

Alcatel-Lucent S.A. (along with three subsidiaries): $137.4 million ($92 million criminal penalty and $45.4 million in disgorgement and interest)

Panalpina World Transport (Holding) Ltd. and Panalpina Inc.: $81.9 million ($70.6 million in criminal fines and $11.3 million in disgorgement)

JGC Corporation of Japan: $218.8 million in criminal fines

IBM: $10 million ($2 million civil penalty, disgorgement of $5.3 million and $2.7 million in prejudgment interest)

Maxwell Technologies: $14.4 million ($8 million in criminal penalties, as well as $6.4 million to settle SEC civil charges)

Comverse: $2.8 million ($1.6 million disgorgement to SEC and $1.2 million criminal fine)

Page 44: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 44

Other FCPA Perils

Shareholder Lawsuits

Faro Technologies: $444,492 in alleged bribes led to $3 million in penalties and resulted in over $7 million settlement with shareholders

Immucor: $19,000 in alleged bribes led to $30,000 in penalties and resulted in $2.5 million settlement with shareholders

Syncor: $113,007 in admitted bribes led to $2 million in penalties and resulted in $15 million settlement with shareholders 7 years later

Internal Investigation Costs

Avon: Spent over $150 million in legal fees on an FCPA investigation, and a shareholder lawsuit is underway

Claims by Foreign Governments

Royal Dutch Shell: after settling with U.S. authorities, required to pay $10 million by the Nigerian government

Alcatel-Lucent: after settling with U.S. authorities, required to pay $10 million by the Costa Rican government

Page 45: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 45

FCPA Trend No. 3: Prosecuting Individuals

As a primary means of deterring bribery, the DOJ has begun to emphasize prosecution of individuals

Numerous individuals settled FCPA-related charges in 2011, including one settlement in which the individual forfeited nearly $149 million, the largest FCPA-related forfeiture imposed on an individual to date (Jeffrey Tesler)

4

5

Page 46: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 46

FCPA Trend No. 4: Widespread Compliance Retooling

Expanding FCPA enforcement, internationalization of business, and Dodd-Frank whistleblower rules have led to massive revision of compliance policies and procedures, including: (i) devising and updating written policies and procedures;

(ii) providing employees and third parties with documented training and certifications;

(iii) performing due diligence on third parties, including distributors, partners, joint ventures, and purported charities;

(iv) vetting the provision of gifts, meals, and other hospitalities to officials in both the public and private sector; and

(v) effectively evaluating and investigating red flags and whistleblower reports.

Page 47: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP

Questions?

Page 48: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP 48

Contact Information

Robb AdkinsLitigation

San Francisco(415) 591-1411

[email protected]

Jack KnightLitigationCharlotte

(704) [email protected]

Neal MarderLitigation

Los Angeles(213) 615-1728

[email protected] Roesser

LitigationNew York

(212) [email protected]

Casey BergerLitigationHouston

(713) [email protected]

Page 49: © 2012 Winston & Strawn LLP · • Dura Pharmaceuticals, Inc. 2005: inflated purchase price/stock drop alone are insufficient to establish loss causation • Tellabs 2007: inference

© 2012 Winston & Strawn LLP

Thank You.